G. Paul Amminger, MD, PhD

Cannabidiol for Treatment-Resistant Anxiety

August 3, 2022

Treatment resistance affects nearly half of all young patients experiencing moderate-to-severe anxiety. This study investigated the safety and efficacy of cannabidiol for anxiety in young people who previously failed...

Maximus Berger, Emily Li, Simon Rice, et al

Letter to the Editor

Dr McGorry and Colleagues Reply

November 15, 2013

Patrick D. McGorry, Alison R. Yung, Barnaby Nelson, et al

Original Research

Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis: Twelve-Month Outcome

April 15, 2013

Patrick D. McGorry, Barnaby Nelson, Lisa J. Phillips, et al

Original Research

Randomized Controlled Trial of Interventions for Young People at Ultra High Risk for Psychosis: 6-Month Analysis

October 19, 2010

Alison R. Yung, Lisa J. Phillips, Barnaby Nelson, et al

Original Research

The EPPIC Follow-Up Study of First-Episode Psychosis: Longer-Term Clinical and Functional Outcome 7 Years After Index Admission

June 15, 2010

Lisa P. Henry, G. Paul Amminger, Meredith G. Harris, et al

Original Research

Intervention in Individuals at Ultra High Risk for Psychosis: A Review and Future Directions

June 30, 2009

Patrick D. McGorry, Barnaby Nelson, G. Paul Amminger, et al

Original Research

Dosing Quetiapine in Drug-Naive First-Episode Psychosis: A Controlled, Double-Blind, Randomized, Single-Center Study Investigating Efficacy, Tolerability, and Safety of 200 mg/day vs. 400 mg/day of Quetiapine Fumarate in 141 Patients Aged 15 to 25 Years

November 30, 2008

Gregor E. Berger, Tina-Marie Proffitt, Mirabel McConchie, et al

Original Research

Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis: A Randomized, Placebo-Controlled Trial

December 14, 2007

Gregor E. Berger, Tina-Marie Proffitt, Mirabel McConchie, et al

Cannabidiol for Treatment-Resistant Anxiety

Dr McGorry and Colleagues Reply

Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis: Twelve-Month Outcome

Randomized Controlled Trial of Interventions for Young People at Ultra High Risk for Psychosis: 6-Month Analysis

The EPPIC Follow-Up Study of First-Episode Psychosis: Longer-Term Clinical and Functional Outcome 7 Years After Index Admission

Intervention in Individuals at Ultra High Risk for Psychosis: A Review and Future Directions

Dosing Quetiapine in Drug-Naive First-Episode Psychosis: A Controlled, Double-Blind, Randomized, Single-Center Study Investigating Efficacy, Tolerability, and Safety of 200 mg/day vs. 400 mg/day of Quetiapine Fumarate in 141 Patients Aged 15 to 25 Years

Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis: A Randomized, Placebo-Controlled Trial

ELSEWHERE:

FOLLOW US:

G. Paul Amminger, MD, PhD

Cannabidiol for Treatment-Resistant Anxiety

Dr McGorry and Colleagues Reply

Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis: Twelve-Month Outcome

Randomized Controlled Trial of Interventions for Young People at Ultra High Risk for Psychosis: 6-Month Analysis

The EPPIC Follow-Up Study of First-Episode Psychosis: Longer-Term Clinical and Functional Outcome 7 Years After Index Admission

Intervention in Individuals at Ultra High Risk for Psychosis: A Review and Future Directions

Dosing Quetiapine in Drug-Naive First-Episode Psychosis: A Controlled, Double-Blind, Randomized, Single-Center Study Investigating Efficacy, Tolerability, and Safety of 200 mg/day vs. 400 mg/day of Quetiapine Fumarate in 141 Patients Aged 15 to 25 Years

Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis: A Randomized, Placebo-Controlled Trial

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles